ArticleMolecules (Basel, Switzerland)2013
In vitro and in vivo studies of the inhibitory effects of emodin isolated from Polygonum cuspidatum on Coxsakievirus B₄.
Article in Molecules (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 70 citations in OpenAlex.
- Establishment of severe in vitro and in vivo infection models for coxsackievirus B4 and their application in identifying viral virulence determinants.Virologica Sinica · 2026Article
- Therapeutic Potential of Emodin: A Mini-Review of Its Anti-Biofilm and Antimicrobial Effects.Infectious disorders drug targets · 2025Review
- Construction of recombinant fluorescent LSDV for high-throughput screening of antiviral drugs.Veterinary research · 2024Article
- Emodin as an Inhibitor of PRV Infection In Vitro and In Vivo.Molecules (Basel, Switzerland) · 2023Article
- Screening and identification of emodin as an EBV DNase inhibitor to prevent its biological functions.Virology journal · 2023Article
- Antiulcer Activity of Anthraquinone-Flavonoid Complex ofMolecules (Basel, Switzerland) · 2023Article
- Japanese Knotweed Rhizome Bark Extract Inhibits Live SARS-CoV-2 In Vitro.Bioengineering (Basel, Switzerland) · 2022Article
- Promising Role of Emodin as Therapeutics to Against Viral Infections.Frontiers in pharmacology · 2022Review
- Emodin in cardiovascular disease: The role and therapeutic potential.Frontiers in pharmacology · 2022Review
- Mechanism of Emodin in the Treatment of Rheumatoid Arthritis.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- New Approaches on Japanese Knotweed (Plants (Basel, Switzerland) · 2021Review
- Emodin fromViruses · 2021Article
- Identification of the phytobioactive Polygonum cuspidatum as an antiviral source for restricting dengue virus entry.Scientific reports · 2020Article
- Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFRInvestigational new drugs · 2020Article
- Molecular Mechanisms of Action of Emodin: As an Anti-Cardiovascular Disease Drug.Frontiers in pharmacology · 2020Review
- Article
- Bioprocessed Production of Resveratrol-Enriched Rice Wine: Simultaneous Rice Wine Fermentation, Extraction, and Transformation of Piceid to Resveratrol fromFoods (Basel, Switzerland) · 2019Article
- Anti-Herpetic, Anti-Dengue and Antineoplastic Activities of Simple and Heterocycle-Fused Derivatives of Terpenyl-1,4-Naphthoquinone and 1,4-Anthraquinone.Molecules (Basel, Switzerland) · 2019Article
- Variation of Fungal Metabolites in Sorghum Malts Used to Prepare Namibian Traditional Fermented BeveragesToxins · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of effective therapeutics for Coxsackievirus B₄ (CVB₄) infection underscores the importance of finding novel antiviral compounds. Emodin (1,3,8-trihydroxy-6-methylanthraquinone) is one of the natural anthraquinone derivatives obtained from the root and rhizome of Polygonum cuspidatum. In the present study, the possibility of using emodin as a potential antiviral to treat CVB₄ infection was explored in vitro and in mice. Emodin reduced CVB₄ entry and replication on Hep-2 cells in a concentration- and time-dependent manner, with a 50% effective concentration (EC₅₀) of 12.06 μM and selectivity index (SI) of 5.08, respectively. The inhibitory effect of emodin for CVB₄ entry and replication was further confirmed by a quantitative real time PCR (qPCR) assay. The results further showed that the mice orally treated with different dosages of emodin displayed a dose dependent increase of survival rate, body weight and prolonged mean time of death (MTD), accompanied by significantly decreased myocardial virus titers and pathologic scores/lesions. Moreover, emodin could inhibit CVB₄-induced apoptosis in vitro and in vivo. Our results indicated that emodin could be used as potential antiviral in the post-exposure prophylaxis for CVB₄ infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.